Posted by Michael Wonder on 11 Sep 2023
BioLineRx announces FDA approval of Aphexda (motixafortide) in combination with filgrastim to mobilise haematopoietic stem cells for collection and subsequent autologous transplantation in patients with multiple myeloma
11 September 2023 - Aphexda is the first innovation in stem cell mobilisation for multiple myeloma to be approved in the US in a decade.
BioLineRx today announced that the US FDA has approved Aphexda (motixafortide) in combination with filgrastim to mobilise haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.
